Pending downside
18/03/19 -"We have clearly reduced the amount of the expected impairments for the coming years, especially in 2019, as management missed the chance to tidy up the balance sheet fully. So the 'risk' for some ..."
Pages
78
Language
English
Published on
18/03/19
You may also be interested by these reports :
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...